Jeiry Filian

1.3k total citations · 1 hit paper
7 papers, 621 citations indexed

About

Jeiry Filian is a scholar working on Oncology, Surgery and Genetics. According to data from OpenAlex, Jeiry Filian has authored 7 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Surgery and 3 papers in Genetics. Recurrent topics in Jeiry Filian's work include Chronic Lymphocytic Leukemia Research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Urinary and Genital Oncology Studies (3 papers). Jeiry Filian is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Urinary and Genital Oncology Studies (3 papers). Jeiry Filian collaborates with scholars based in United States, Switzerland and France. Jeiry Filian's co-authors include Timothy P. Hughes, Andreas Hochhaus, Jerald P. Radich, Brian Druker, John M. Goldman, Insa Gathmann, Richard A. Larson, Stephen G. O’Brien, François Guilhot and Manisha Mone and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Urology.

In The Last Decade

Jeiry Filian

6 papers receiving 602 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

2009 444 citations Michael W. Deininger, Stephen G. O’Brien et al. Blood profile →

Peers

Countries citing papers authored by Jeiry Filian

Since Specialization

Citations

This map shows the geographic impact of Jeiry Filian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeiry Filian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeiry Filian more than expected).

Fields of papers citing papers by Jeiry Filian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeiry Filian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeiry Filian. The network helps show where Jeiry Filian may publish in the future.

Co-authorship network of co-authors of Jeiry Filian

This figure shows the co-authorship network connecting the top 25 collaborators of Jeiry Filian. A scholar is included among the top collaborators of Jeiry Filian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeiry Filian. Jeiry Filian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial 2025 ·European Urology ·Matthew D. Galsky, Michiel S. van der Heijden, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Ruiyun Jiang, Jeiry Filian, Lily Wang, (unknown), Guru Sonpavde	0
2	Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. 2025 ·Journal of Clinical Oncology ·Michiel Simon Van Der Heijden, Matthew D. Galsky, Thomas Powles, Andrea Necchi, Dingwei Ye, Pengfei Zhang, Aristotelis Bamias, (unknown), Michel Pavic, Jens Bedke, Ja Hyeon Ku, Mauricio Burotto, Gwénaëlle Gravis, Jan Oldenburg, Yoshihiko Tomita, Yüksel Ürün, Jeiry Filian, (unknown), Emmanouil G. Spanakis, Guru Sonpavde	3
3	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. 2024 ·Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	11
4	Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8 2023 ·The Breast ·Guy Jérusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruíz-Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, (unknown), Antonella Mazzei, Sara M. Tolaney	23
5	Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers 2011 ·The Journal of Clinical Pharmacology ·Ophelia Yin, Marc S. Rudoltz, Ivana Galetić, Jeiry Filian, (unknown), Wei Zhou, Joseph M. Custodio, Georg Golor, Horst Schran	9
6	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. breakdown → 2009 ·Blood ·Michael W. Deininger, Stephen G. O’Brien, François Guilhot, John M. Goldman, Andreas Hochhaus, Timothy P. Hughes, Jerald P. Radich, Alan K. Hatfield, Manisha Mone, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, Brian Druker	444
7	International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM) 2008 ·Blood ·Stephen G. O’Brien, François Guilhot, John M. Goldman, Andreas Hochhaus, Timothy P. Hughes, Jerald P. Radich, Marc S. Rudoltz, Jeiry Filian, Insa Gathmann, Brian Druker, Richard A. Larson	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact